VEROVIR PHARMA: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
VEROVIR PHARMA
Largest movements
- Cash +€325,403
up €325,403 (+343%), from €94,875 to €420,278
mainly Receivables within one year (+€232,898) and Depreciation (+€54,608)
- Receivables within one year -€232,898
down €232,898 (-93.0%), from €250,446 to €17,548
of which Other amounts receivable: -€214,240
- Tangible fixed assets -€47,431
down €47,431 (-7.6%), from €624,040 to €576,609
of which Land and buildings: -€26,363
- Profit (loss) carried forward +€49,471
up €49,471 (+7.9%), from €622,421 to €671,892
- Gross operating margin +€62,965
up €62,965 (+69.1%), from €91,061 to €154,027
- Write-downs +€23,344
new in 2025: €23,344
- Taxes +€8,738
up €8,738 (+112%), from €7,811 to €16,549
- Other operating charges +€3,691
up €3,691 (+58.0%), from €6,360 to €10,051
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €969,748 | €1,016,871 | +€47,123 | +4.9% |
| Formation expenses | 20 | €0 | €0 | = | |
| Fixed assets | 21/28 | €624,427 | €576,996 | -€47,431 | -7.6% |
| Tangible fixed assets | 22/27 | €624,040 | €576,609 | -€47,431 | -7.6% |
| Land and buildings | 22 | €480,834 | €454,471 | -€26,363 | -5.5% |
| Plant, machinery and equipment | 23 | €143,206 | €122,139 | -€21,068 | -14.7% |
| Financial fixed assets | 28 | €387 | €387 | = | 0.0% |
| Current assets | 29/58 | €345,321 | €439,875 | +€94,554 | +27.4% |
| Amounts receivable within one year | 40/41 | €250,446 | €17,548 | -€232,898 | -93.0% |
| Trade receivables | 40 | €27,755 | €9,097 | -€18,658 | -67.2% |
| Other amounts receivable | 41 | €222,690 | €8,451 | -€214,240 | -96.2% |
| Cash at bank and in hand | 54/58 | €94,875 | €420,278 | +€325,403 | +343% |
| Deferred charges and accrued income | 490/1 | - | €2,049 | +€2,049 | |
| Total equity and liabilities | 10/49 | €969,748 | €1,016,871 | +€47,123 | +4.9% |
| Equity | 10/15 | €955,661 | €1,005,132 | +€49,471 | +5.2% |
| Contributions | 10/11 | €198,400 | €198,400 | = | 0.0% |
| Capital | 10 | €198,400 | €198,400 | = | 0.0% |
| Issued capital | 100 | €198,400 | €198,400 | = | 0.0% |
| Reserves | 13 | €134,840 | €134,840 | = | 0.0% |
| Non-distributable reserves | 130/1 | €19,840 | €19,840 | = | 0.0% |
| Legal reserve | 130 | €19,840 | €19,840 | = | 0.0% |
| Distributable reserves | 133 | €115,000 | €115,000 | = | 0.0% |
| Profit (loss) carried forward | 14 | €622,421 | €671,892 | +€49,471 | +7.9% |
| Amounts payable | 17/49 | €14,087 | €11,739 | -€2,348 | -16.7% |
| Amounts payable within one year | 42/48 | €14,087 | €11,739 | -€2,348 | -16.7% |
| Current portion of amounts payable after more than one year | 42 | - | €700 | +€700 | |
| Trade debts | 44 | €2,509 | €3,340 | +€831 | +33.1% |
| Suppliers | 440/4 | €2,509 | €3,340 | +€831 | +33.1% |
| Advances received on contracts in progress | 46 | €3,251 | - | -€3,251 | |
| Taxes, remuneration and social security | 45 | €4,427 | €3,566 | -€861 | -19.4% |
| Taxes | 450/3 | €4,427 | €3,566 | -€861 | -19.4% |
| Other amounts payable | 47/48 | €3,900 | €4,133 | +€233 | +6.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €54,366 | €54,608 | +€242 | +0.4% |
| Write-downs on stocks, contracts in progress and trade receivables: additions (reversals) | 631/4 | - | €23,344 | +€23,344 | |
| Other operating charges | 640/8 | €6,360 | €10,051 | +€3,691 | +58.0% |
| Gross operating margin | 9900 | €91,061 | €154,027 | +€62,965 | +69.1% |
| Operating profit (loss) | 9901 | €30,336 | €66,023 | +€35,688 | +118% |
| Financial income | 75/76B | €57 | €0 | -€57 | -100.0% |
| Recurring financial income | 75 | €57 | €0 | -€57 | -100.0% |
| Financial charges | 65/66B | €26 | €3 | -€23 | -89.4% |
| Recurring financial charges | 65 | €26 | €3 | -€23 | -89.4% |
| Profit (loss) for the period before taxes | 9903 | €30,367 | €66,021 | +€35,654 | +117% |
| Income taxes | 67/77 | €7,811 | €16,549 | +€8,738 | +112% |
| Profit (loss) for the period | 9904 | €22,556 | €49,471 | +€26,916 | +119% |
| Profit (loss) for the period to be appropriated | 9905 | €22,556 | €49,471 | +€26,916 | +119% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 13 October 2026 via checked.be.